Here an overview of Antibe by Zacks from last year with a valuation based on getting a partner to advance phase III and commercialize the drug. Zacks gives it a 50% chance of approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.